Relay Therapeutics, Inc. (RLAY) has been beaten down lately with too much selling pressure. While the stock has lost 24% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscill ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | |----------------------------------------------------------------------------|------------------------------------------------------- ...

Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected to fund operations into second half of 2027 Cambridge, Mass. – November 6, 2024 – Re ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected to fund operations into second half of 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company trans ...

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming ...

Relay Therapeutics, Inc. (RLAY) shares soared 6.7% in the last trading session to close at $8.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.8% gain over the past four weeks. The sudden surge in the stock price can be attributed to a positive investor mindset regarding the company's pipeline progress. Relay Therapeutics is leveraging its Dynamo platform to initially focus on precision oncology. The company has several can ...

Investors weren't happy with the company's latest effort at capital-raising. Relay Therapeutics (RLAY -13.83%), one of a clutch of biotech companies that are developing treatments in the wide and potentially lucrative oncology field, didn't have a good Wednesday on the stock market. This followed the latest news about the biotech company's upcoming secondary share issue, which many investors consider to be unacceptably dilutive. On the back of that news, Relay's stock closed the day almost 14% lower, in con ...

CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 4,285,714 share ...

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor). The clinical benefit rate (CBR) was 57% in heavily pretreated patients. RLY-2608 is a pan-mutant and isoformselective inhibitor of PI3Kα. Oppenheimer downgraded Relay Therapeutics, noting the upcoming data from competitors. "We believe that approved PI ...

Shares of Relay Therapeutics (RLAY) soared 52.4% on Sept. 9 after the company announced positive interim data from the early-stage study of its lead investigational candidate, RLY-2608, to treat heavily pretreated breast cancer patients. The enrolled population included PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer (MBC) patients who received the combo regimen of twice-daily, 600 mg dose of RLY-2608 and AstraZeneca's (AZN) Faslodex (fulvestrant). Interim data from the study showed t ...